Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Companyâ€™s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change
26-10-01	US$0.9200	+3.66%
26-09-30	US$0.8875	-7.60%
26-09-29	US$0.9605	-5.83%
26-09-28	US$1.020	-6.42%
26-09-25	US$1.090	-3.54%

Delayed Quote Nasdaq

More quotes

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq 16:30:00 2026-10-01 EDT			5-day change	1st Jan Change
0.9200 ^USD	+3.66%		-22.83%	-72.52%

08-14	Alaunos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-29	Alaunos Therapeutics Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment For Body Fat Percentage In 48-Day DIO Mouse Study	CI

Market Cap	2.34M 2.08M 1.94M 1.77M 3.33M 225M 3.38M 23.49M 9.09M 115M 8.78M 8.58M 368M	P/E 2024	-0.65x	P/E 2025	-1.47x
Enterprise Value	952K 846K 791K 721K 1.36M 91.68M 1.38M 9.57M 3.7M 46.69M 3.58M 3.5M 150M	EV / Sales 2024	195,938,500x	EV / Sales 2025	1,164,761,400x
Free-Float	86.72%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq	TCRT	Delayed
CBOE	TCRT	Real-time

08-14	Alaunos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-29	Alaunos Therapeutics Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment For Body Fat Percentage In 48-Day DIO Mouse Study	CI
05-26	Alaunos Therapeutics Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies	CI
05-18	Alaunos reports preclinical ALN1003 data showing effects on insulin-resistance-related biomarkers and liver histology in diet-induced obesity models	RE
05-18	Alaunos Therapeutics Announces Updated Preclinical Data For ALN1003	CI
05-15	Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-31	Alaunos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	Alaunos Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
03-05	Price Adrian Issues a Letter to Alaunos Therapeutics Inc	CI
03-02	Alaunos Therapeutics, Inc. Announces Early Data from Two Non-Good Laboratory Practice Diet-Induced Obesity Mouse Studies Evaluating ALN1003	CI
03-02	Alaunos Therapeutics announces positive preclinical proof-of-concept data for ALN1003, a differentiated non-hormonal oral treatment for obesity and related metabolic disorders	RE
02-24	Price Adrian Issues a Letter to Alaunos Therapeutics Inc	CI
01-08	Alaunos Therapeutics terminates engagement with Cantor Fitzgerald	RE

Alaunos Therapeutics, Inc. Stock

Stocks

TCRT

US98973P3091

Biotechnology & Medical Research

Valuation: Alaunos Therapeutics, Inc.

Chart: Alaunos Therapeutics, Inc.

Latest news: Alaunos Therapeutics, Inc.

Analysts' recommendations: Alaunos Therapeutics, Inc.

Press Releases: Alaunos Therapeutics, Inc.

News in other languages: Alaunos Therapeutics, Inc.

Quotes and Performance

Managers and Directors: Alaunos Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

23-08-16	HC Wainwright Downgrades Alaunos Therapeutics to Neutral From Buy	MT
23-08-15	Laidlaw Downgrades Alaunos Therapeutics to Hold From Buy	MT
22-10-04	Wells Fargo Assumes Alaunos Therapeutics at Overweight with $3 Price Target	MT
22-07-15	Cantor Fitzgerald Assumes Alaunos Therapeutics at Overweight with $3 Price Target	MT
22-05-04	Wells Fargo Upgrades Alaunos Therapeutics to Overweight From Equalweight	MT

09-18	Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules	AQ
08-14	Ziopharm: Q2 Earnings Snapshot	AQ
06-29	Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study	AQ
05-26	Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies	AQ
05-18	Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models	AQ

15-06-30	Alibaba : Les valeurs à suivre sur les marchés américains
15-06-30	USA-Les valeurs à suivre à Wall Street

Manager	Title	Age	Since
Holger Weis CEO	Chief Executive Officer	63	2025-07-01
Ferdinand Groenewald DFI	Director of Finance/CFO	42	2025-02-21

Director	Title	Age	Since
Jaime Vieser BRD	Director/Board Member	56	2020-12-15
Holger Weis CHM	Chairman	63	2023-09-21
Robert Postma BRD	Director/Board Member	72	2021-02-04

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/6/26	Holger Weis	Free	Chief Executive Officer	4,363	0.1787%
7/23/26	Michael Jerman	Free	Director	8,138	0.3332%
7/23/26	Holger Weis	Free	Chief Executive Officer	4,568	0.1870%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALAUNOS THERAPEUTICS, INC.	+3.66%	-22.83%	-	-	2.34M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.41B
ARGENX SE	-1.19%	-1.56%	+24.40%	+78.16%	59.26B
LONZA GROUP AG	+0.89%	-0.49%	+4.42%	+34.70%	47.14B
IQVIA HOLDINGS INC.	-3.02%	-5.20%	+27.94%	+32.51%	42.91B
REVOLUTION MEDICINES, INC.	+0.31%	+3.02%	+348.95%	+643.82%	44.13B
BEONE MEDICINES AG	-1.96%	-0.33%	+7.04%	+99.46%	40.79B
CELLTRION, INC.	+3.32%	+3.49%	+10.10%	+51.23%	30.77B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.63%	+22.72%	29.31B
INSMED INCORPORATED	-4.86%	-10.66%	-26.27%	+330.06%	23.71B
Average	-0.13%	-2.75%	+52.84%	+154.09%	39.24B
Weighted average by Cap.	-0.00%	-0.32%	+58.02%	+145.78%

	2024	2025
Net sales	0.01 0.01 0.01 0.01 0.01 0.96 0.01 0.1 0.04 0.49 0.04 0.04 1.57	0 0 0 0 0.01 0.48 0.01 0.05 0.02 0.25 0.02 0.02 0.79
Net income	-4.68M -4.16M -3.89M -3.54M -6.67M -450M -6.76M -47.02M -18.2M -229M -17.57M -17.19M -737M	-4.18M -3.71M -3.47M -3.16M -5.95M -402M -6.03M -41.96M -16.24M -205M -15.68M -15.34M -658M
Net Debt	-1.09M -969K -906K -826K -1.55M -105M -1.58M -10.96M -4.24M -53.5M -4.1M -4.01M -172M	-1.38M -1.23M -1.15M -1.05M -1.97M -133M -2M -13.92M -5.39M -67.91M -5.2M -5.09M -218M